Open Access
CC BY-NC-ND 4.0 · South Asian J Cancer 2024; 13(02): 110-113
DOI: 10.1055/s-0043-1763282
Original Article
Head and Neck Cancer

Surgical Site Infection in Head and Neck Cancer Patients: Observations from A Tertiary Care Hospital

Authors

  • Surlu Vidya Rao

    1   Department of Hospital Administration, Father Muller Medical College Hospital, Kankanady, Mangalore, Karnataka, India
  • Paul Simon

    2   Department of Radiation Oncology, Father Muller Medical College Hospital, Kankanady, Mangalore, Karnataka, India
  • Elroy Saldanha

    3   Department of General Surgery, Father Muller Medical College Hospital, Kankanady, Mangalore, Karnataka, India
  • Rekha Boloor

    4   Department of Microbiology/Hospital Infection Control, Father Muller Medical College Hospital, Kankanady, Mangalore, Karnataka, India
  • Ramakrishna Pai Jakribettu

    4   Department of Microbiology/Hospital Infection Control, Father Muller Medical College Hospital, Kankanady, Mangalore, Karnataka, India
  • Manjeshwar Shrinath Baliga

    5   Father Muller Research Centre, Kankanady, Mangalore, Karnataka, India
 

Abstract

Zoom
Ramakrishna Pai Jakribettu

Background Surgical site infections (SSIs) in head and neck cancer (HNC) patients can significantly affect the outcome of the surgery. Appropriate antimicrobial prophylaxis is needed for prevention of SSI.

Aim To study the causative agents causing SSI among the HNC patients and their drug resistance pattern.

Materials and Methods This was a retrospective study. The antibiotic suspectibility pattern of the aerobic bacteria isolated from the wound infection in the patients underwent surgery for head and neck cancer, admitted from January 2015 to December 2016 were added in the study. The demographic details of patients, pathogens isolated, and their antimicrobial susceptibility were collected, entered into Microsoft Excel, and statistical analysis was done as per percentage of isolates and drug resistance.

Results A total of 130 culture-positive pus samples were included in the study. The majority of the samples were from males (71.5%), one-third of the patients belonged to the sixth decade of their life. Buccal mucosa and tongue were the common cancer in the head and neck region. The common gram-negative pathogens were Klebsiella sp. and Acinetobacter sp. and Staphylococcus aureus and Enterococcus sp. among the gram-positive bacteria. Methicillin-resistant S. aureus isolation rate was noted to be as high as 64.28%. High levels of resistance to aminopenicillins, third generation cephalosporins, co-trimoxazole and fluoroquinolones among the gram-negative pathogens. Anti-MRSA drugs such as vancomycin, linezolid, and teicoplanin resistance was not seen among S. aureus.

Conclusion The resistance pattern among the pathogens isolated from SSI in HNC patients is alarming. So, implementation of strict infection control practices to prevent SSI rather than treating them with high end antimicrobials is the best option.


Introduction

Head and neck cancers are of very much public health importance, accounting for more than 650,000 cases around 330,000 deaths annually.[1] The head and neck cancers are the cancers that are occurring in the oral cavity, pharynx, nasal cavities, and paranasal sinuses, ears, eyes, and orbit, scalp, and salivary glands.[2] The site of occurrence of these cancers interferes with some of the basic functions of life such as swallowing, breathing, and higher functions such as speech, hearing, vision, smelling and taste.[3]

There is gender predisposition toward men in head and neck cancers. The major pre-disposing factors being excess consumption of alcohol and tobacco, were postulated more than two and half decade ago.[4] This causes cancer to be from diverse origin such as epithelium, especially squamous cell carcinoma, others being lymphocytes (lymphoma), soft tissue (sarcoma), and endocrine tumors.[5] Thus requires a multidisciplinary approach with surgery, radiotherapy, chemotherapy, reconstructive surgery, speech therapy, psychological support.[6]

For improved curative rates, wide resection and reconstruction are the most accepted mode of treatment.[7] However, the prognosis is greatly affected when the surgical site gets infected, causing increased treatment cost, prolonged length of stay in hospital, and delayed in other treatments such as chemo- or radiotherapy.[8]

The surgical site infections (SSIs) can be prevented with appropriate pre-surgical antimicrobial prophylaxis, following aseptic precautions during the surgery and postoperative care. Thus, to initiate appropriate antimicrobial prophylaxis, the flora causing SSIs has to be known with its antimicrobial resistance pattern. So, this study was undertaken to study the pathogens causing SSI and their antimicrobial resistance pattern.


Materials and Methods

This is a retrospective study carried out in the department of Microbiology/Infection control of Fr Muller Medical College Hospital, Mangalore, India. The data on the antibiotic sensitive pattern of the aerobic bacteria isolated from the wound infection in the patients undergoing surgery for head and neck cancer, admitted from January 2017 to December 2018, were collected. The demographic details were collected from the medical records departments, and microbiological data were collected from the clinical laboratory, after obtaining permission from the Institutional Ethics Committee.

The culture of the pus sample was done on sheep blood agar and MacConkey agar and pathogens isolated were identified according to the standard microbiological procedure. Antimicrobial susceptibility test was done as per the Clinical Laboratory Standard Institute (CLSI) guidelines.[9] The antimicrobial susceptibility was tested against ampicillin (10 μg), ceftriaxone/ceftazidime/cefoxitin (30 μg), cotrimoxazole (25 μg), gentamicin (10 μg), amikacin (30 μg), ciprofloxacin (5 μg), and levofloxacin (5 μg). Additionally, piperacillin/tazobactam (100/10 μg), meropenem (10 μg) for gram-negative pathogens and erythromycin (15 μg), clindamycin (2 μg), vancomycin (30 μg), linezolid (30 μg), teicoplanin (30 μg) for gram-positive pathogens were tested. The collected data were entered into Microsoft Excel, and statistical analysis was done as per percentage of isolates and drug resistance.


Results

A total of 130 culture-positive pus samples were detected during the study period. The majority of the samples were from males (71.5%) and one-third of the patients belonged to the sixth decade of their life ([Table 1]). Most patients included in the study had cancer of buccal mucosa (46, 35.38%), followed by tongue (27, 20.77%). From the 130 exudate samples, 235 pathogens were isolated. The gram-negative pathogens accounted for 158 (67.23%) and gram-positive pathogens (77, 32.77%). Klebsiella sp. outnumbered among the gram-negative pathogens followed by Acinetobacter sp. ([Table 2]). Among the gram-positive, Staphylococcus aureus was the commonest followed by Enterococcus sp.([Table 2]). Methicillin-resistance isolation was noted to be as high as 64.28% and 63.9% among coagulase-negative Staphylococcus (9/14) and S. aureus (23/36), respectively. The study of antimicrobial susceptibility revealed a high level of resistance to aminopenicillins, third-generation cephalosporins, co-trimoxazole, and fluoroquinolones among the gram-negative pathogens. The high-end antimicrobials such as β lactam-β lactamase inhibitor combination, carbapenems, and aminoglycosides were sensitive to around 45% of the Klebsiella isolates. However, in case of Acinetobacter sp., resistance to high-end antimicrobials is more than 80% ([Table 3]). Among E. coli and other gram-negative pathogens more than 55% were susceptible to high-end antimicrobials. Only Acinetobacter sp. isolates were the difficult to be treated among the gram-negative pathogens. Among the gram-positive pathogens, MRCoNS and MRSA isolation rate was high. The penicillin, 3GC, fluoroquinolones resistance was very high. Anti-MRSA drugs such as vancomycin, linezolid, and teicoplanin resistance was not seen among S. aureus and Enterococcus sp. isolated, but resistance to linezolid was emerging among the CoNS ([Table 4]).

Table 1

Demographic details of head and neck cancer patients

Parameters

No. of patients (n = 130)

%

 Age

<30

3

2.31

31–40

19

14.62

41–50

24

18.46

51–60

43

33.08

61–70

31

23.85

71–80

6

4.62

81–90

4

3.08

 Gender

Male

93

71.54

Female

37

28.46

 Site of tumor

Buccal mucosa

46

35.38

Tongue

27

20.77

Oral cavity

14

10.77

Alveolus

12

9.23

Larynx

11

8.46

RMT

5

3.85

Maxilla

3

2.31

Thyroid

3

2.31

Floor of mouth

3

2.31

Glottis

2

1.54

Pharynx

2

1.54

PFS

1

0.77

Metastasis of unknown origin

1

0.77

Table 2

Distribution of pathogens isolated from SSI of head and neck cancer patients

Gram-negative

158

67.23

Klebsiella sp

56

23.83

Acinetobacter sp

36

15.32

Escherichia coli

30

12.77

Pseudomonas aeruginosa

19

8.09

Citrobacter sp.

9

3.83

Proteus sp.

8

3.40

Gram-positive

77

32.77

Staphylococcus aureus

36

15.32

Enterococcus sp.

16

6.81

Coagulase-negative Staphylococcus (CoNS)

14

5.96

Corynebacterium sp.

11

4.68

235

100.00

Table 3

Antimicrobial resistance pattern among gram-negative pathogens isolated from SSI

Klebsiella sp.

(56)

Acinetobacter sp.

(36)

Escherichia coli

(30)

Pseudomonas aeruginosa (19)

Citrobacter sp.

(9)

Proteus sp.

(8)

Ampicillin

100.00

93.33

100.00

100.00

3GC

98.21

97.22

90.00

21.05

77.78

62.50

Cotrimoxazole

69.64

75.00

80.00

88.89

62.50

Gentamicin

42.86

91.67

43.33

15.79

22.22

75.00

Amikacin

41.07

80.56

6.67

15.79

11.11

37.50

Ciprofloxacin

75.00

94.44

86.67

15.79

88.89

50.00

Levofloxacin

53.57

72.22

83.33

10.53

55.56

37.50

Piptaz

75.00

91.67

40.00

15.79

33.33

0.00

Meropenem

53.57

83.33

23.33

5.26

0.00

25.00

Table 4

Antimicrobial resistance pattern among the Gram positive pathogens isolated from SSI

Staphylococcus aureus

(36)

Enterococcus sp.

(16)

Coagulase-negative Staphylococcus

(14)

Ampicillin

94.44

43.75

100.00

3GC

63.89

71.43

Cotrimoxazole

41.67

35.71

Gentamicin

50.00

68.75

50.00

Amikacin

27.78

0.00

14.29

Ciprofloxacin

91.67

68.75

50.00

Levofloxacin

69.44

62.50

35.71

Erythromycin

52.78

0.00

71.43

Clindamycin

41.67

0.00

57.14

Vancomycin

0.00

0.00

0.00

Teicoplanin

0.00

0.00

0.00

Linezolid

0.00

0.00

7.14


Discussion

Surgical site infection is one of the important nosocomial infections, which is caused by highly antimicrobial-resistant bacteria. In turn, it causes prolonged hospital stay, increased antimicrobial therapy, medical costs, comorbidity, emotional trauma, further reducing the immune status of the cancer patients, leading to further delay in other adjuvant therapies.[10] In Mexico, around 8% of SSI was reported among 23,421 surgeries performed in a 7 years retrospective study. In another study on 110 oral cancer patterns, SSI rate was noted as 22.7%.[11] Similarly, in 260 French patients with head and neck squamous cell carcinomas undergoing surgical procedure, 117 (45%) were infected.[8] The males were more prone to wound infection compared to females in head and neck cancers in the French population,[8] similar trend is found in our study.

Various studies have reported different bacterial flora causing SSI in cancer patients, depending on the age of patient, population treated, and site of cancer. Among the pathogens isolated, gram-negative E. coli accounted for (27.5%), followed by gram-positive, S. aureus (16.3%).[12] Similarly, an Indian study reported E. coli being the predominant pathogen causing SSI.[13] However, in our study, even though gram-negative bacilli outnumbered, Klebsiella sp. was as the predominant pathogen. This emphasis the flora causing SSI can vary among the hospitals. In developed countries such as the USA, gram-positive pathogen, S. aureus continues to be the leading causing of SSI in cancer patients irrespective of site of infection.[14]

The study of resistance pattern among gram-negative pathogens revealed a high level of resistance to commonly used antimicrobials such as aminoglycosides, fluoroquinolones were ineffective in the study, similar to our isolates.[12] In an Indian study, high level of resistance, i.e., around 63% to third-generation cephalosporins such as cefotaxime and ceftazidime were observed among the gram-negative pathogens in SSI in cancer patients.[13] The predominant gram-negative pathogens such as Klebsiella, Acinetobacter, and E. coli had resistance to a range of 90 to 98% to 3GC in our patients. The resistance to β lactam-β lactamase inhibitor and carbapenems was reported to as high as 85% in pathogens causing SSI an Egyptian patients[15]; similarly, we reported a resistance range from 75 to 92% in various isolates. Among the gram-positive isolates, Staphylococcus sp. and Enterococcus sp. are the common pathogens causing SSI in cancer patients.[13] [15] The methicillin resistance have be reported as high as 40%. We had MRSA isolation rate (64.28%) among S. aureus higher than other studies[12] [13] [16] [17] but higher rates are been reported in Egyptian patients.[15]


Conclusion

In the present study, we have studied the pathogens causing SSI in head and neck cancer patients. This study has helped to identify resistance patterns in both gram-negative and gram-positive pathogens causing SSI and highlights that the antimicrobial resistance among these pathogens is occurring at a very alarming rate. So, the infection control practices need to be implemented strictly in these immunocompromised cancer patients. The SSI in the cancer patients studied denotes that the pathogens are predominantly gram-negative Klebsiella sp. and Acinetobacter sp., which are multi-drug resistant. Among gram-positive, MRSA and Enterococcus sp. are of concern, the treatment option available is very less. So, greater responsibilities lies on the health care workers on implementation of strict infection control practices to prevent SSI rather than treating them.



Conflict of Interest

None declared.


Address for correspondence

Ramakrishna Pai Jakribettu, MD, MBA, Vice Principa/Professor & Head
Department of Microbiology, Malabar Medical College Hospital & Research Centre
Ulliyeri, Kerala 673323
India   

Publikationsverlauf

Artikel online veröffentlicht:
09. März 2023

© 2023. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India


Zoom
Ramakrishna Pai Jakribettu